Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Other financing activities (2016 - 2022)

Historic Other financing activities for Myriad Genetics (MYGN) over the last 12 years, with Q3 2022 value amounting to $700000.0.

  • Myriad Genetics' Other financing activities changed N/A to $700000.0 in Q3 2022 from the same period last year, while for Dec 2024 it was $700000.0, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2023, which is 14285.71% up from last year.
  • Per Myriad Genetics' latest filing, its Other financing activities stood at $700000.0 for Q3 2022.
  • In the past 5 years, Myriad Genetics' Other financing activities registered a high of $129.6 million during Q2 2019, and its lowest value of -$500000.0 during Q3 2019.
  • Its 5-year average for Other financing activities is $14.8 million, with a median of $1.5 million in 2019.
  • The largest annual percentage gain for Myriad Genetics' Other financing activities in the last 5 years was 85000.0% (2019), contrasted with its biggest fall of 12631.58% (2019).
  • Quarter analysis of 5 years shows Myriad Genetics' Other financing activities stood at $2.6 million in 2018, then plummeted by 30.77% to $1.8 million in 2019, then tumbled by 44.44% to $1.0 million in 2020, then grew by 20.0% to $1.2 million in 2021, then crashed by 41.67% to $700000.0 in 2022.
  • Its last three reported values are $700000.0 in Q3 2022, $1.2 million for Q1 2021, and $1.0 million during Q3 2020.